Sareum Holdings plc (AIM: SAR), the structure-based drug discovery and services business, is pleased to announce its financial results for the six month period ended 31 December 2004.

Business Highlights to date:

  • Successful flotation on AIM - October 2004
  • Collaborative agreement with Inpharmatica - November 2004
  • Collaboration with Millennium Pharmaceuticals, Inc - November 2004
  • Drug discovery collaboration with EiRx Therapeutics plc - December 2004
  • Collaboration with Cancer Research Technology Limited - December 2004
  • Collaboration with undisclosed UK pharmaceutical company - December 2004

Dr Tim Mitchell, CEO of Sareum Holdings, said: "Our debut as a publicly quoted company has been a successful one. Since joining the AIM Market we have announced several collaborative and fee-for-service collaborations. Our business development activities are expanding, we have fully equipped laboratories in Cambridge and together with our strong cash position, I believe Sareum is well positioned for a healthy year ahead."

For further information please contact:

Sareum Holdings 01223 497700
Tim Mitchell, Chief Executive Officer

Buchanan Communications 020 7466 5000
Tim Anderson, Mark Court, Mary-Jane Johnson

Results available as PDF document: Financial Results 2004